JP4945692B2 - Cell-utilized skin external preparation composition and method for producing the same - Google Patents

Cell-utilized skin external preparation composition and method for producing the same Download PDF

Info

Publication number
JP4945692B2
JP4945692B2 JP2011111820A JP2011111820A JP4945692B2 JP 4945692 B2 JP4945692 B2 JP 4945692B2 JP 2011111820 A JP2011111820 A JP 2011111820A JP 2011111820 A JP2011111820 A JP 2011111820A JP 4945692 B2 JP4945692 B2 JP 4945692B2
Authority
JP
Japan
Prior art keywords
peptide
external preparation
fermented product
skin external
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011111820A
Other languages
Japanese (ja)
Other versions
JP2011173921A (en
Inventor
利孝 岡田
賢司 藤澤
寛子 ▲高▼▲橋▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyo Hakko Co Ltd
Original Assignee
Toyo Hakko Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Hakko Co Ltd filed Critical Toyo Hakko Co Ltd
Priority to JP2011111820A priority Critical patent/JP4945692B2/en
Publication of JP2011173921A publication Critical patent/JP2011173921A/en
Application granted granted Critical
Publication of JP4945692B2 publication Critical patent/JP4945692B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/011Hydrolysed proteins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • A23L33/155Vitamins A or D
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/742Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/671Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Abstract

A fermented product composition and a cosmetic composition comprising a fermented product, which is obtained by fermenting peptides originating in rice bran and beans by using Bacillus subtilis, and at least one member selected from peptides and vitamin A analogs. A production method comprising a mixing step wherein a fermented product, which is obtained by fermenting peptides originating in rice bran and beans by using Bacillus subtilis, is mixed with at least one member selected from peptides and vitamin A analogs.<I/>

Description

本発明は、細胞賦活用皮膚外用剤組成物及びその製造方法に関する。更に詳しくは、本発明は、安全性が高く、コラーゲン合成作用等に優れた細胞賦活用皮膚外用剤組成物及びその製造方法に関する。   The present invention relates to a cell-utilizing skin external preparation composition and a method for producing the same. More specifically, the present invention relates to a cell-utilizing skin external preparation composition that is highly safe and excellent in collagen synthesis and the like, and a method for producing the same.

従来より、米ぬか等を発酵させて得られる発酵物を含有する皮膚外用剤等の化粧品等が知られている。例えば、特許文献1には、発酵糠類を含有する化粧品組成物及びそれを用いた化粧品が開示されている。特許文献1において、この化粧品は、保湿性に優れ、皮膚に塗布した際の刺激が少なく、炎症が発生し難く快適であることが記載されている。また、特許文献2には、米ぬかと大豆ペプチドとを枯草菌により発酵させ、その後、精製処理して得られる皮膚外用剤原料の製造方法が開示されている。特許文献2において、この皮膚外用剤原料は安全性が高く、皮膚の活性を高めることができることが記載されている。   Conventionally, cosmetics such as a skin external preparation containing a fermented product obtained by fermenting rice bran and the like are known. For example, Patent Document 1 discloses a cosmetic composition containing a fermented rice cake and a cosmetic using the same. Patent Document 1 describes that this cosmetic product is excellent in moisture retention, has little irritation when applied to the skin, is less likely to cause inflammation, and is comfortable. Patent Document 2 discloses a method for producing a skin external preparation raw material obtained by fermenting rice bran and soybean peptide with Bacillus subtilis and then purifying it. Patent Document 2 describes that this skin external preparation raw material has high safety and can enhance skin activity.

特開2004−262829号公報JP 2004-262829 A 特開平8−104647号公報JP-A-8-104647

特許文献1及び2記載の発酵物を皮膚外用剤等の化粧品に配合することによる効能は多い。例えば、この発酵物を配合した皮膚外用剤等の化粧品は、しわ、しみ、たるみ等を抑えることができ、しもやけ、あかぎれ及び肌荒れ等を予防することができる。また、この発酵物を配合した皮膚外用剤等の化粧品では、創傷治癒及び火傷等の症状の改善等の効能が得られる。   There are many effects by mix | blending the fermented material of patent document 1 and 2 with cosmetics, such as a skin external preparation. For example, cosmetics such as an external preparation for skin containing this fermented product can suppress wrinkles, stains, sagging, and the like, and can prevent dullness, redness, rough skin, and the like. Moreover, in cosmetics such as an external preparation for skin containing this fermented product, effects such as wound healing and improvement of symptoms such as burns can be obtained.

本発明は、安全性が高く、コラーゲン合成作用等に優れた細胞賦活用皮膚外用剤組成物及びその製造方法を提供することを目的とする。 An object of the present invention is to provide a cell-utilizing skin external preparation composition that is highly safe and excellent in collagen synthesis action and the like, and a method for producing the same.

本発明は以下のとおりである。
〔1〕米ぬかと豆類由来ペプチドとを枯草菌により発酵させた後精製して得られる発酵物と、大豆タンパク質が加水分解されたペプチド及び絹ペプチドの少なくとも1種であるペプチドとを、質量比9:1〜1:9の割合で混合することにより得られたことを特徴とする細胞賦活用皮膚外用剤組成物。
〔2〕米ぬかと豆類由来ペプチドとを枯草菌により発酵させた後精製して得られる発酵物と、大豆タンパク質が加水分解されたペプチド及び絹ペプチドの少なくとも1種であるペプチドとを、質量比9:1〜1:9の割合で混合する混合工程を備えることを特徴とする細胞賦活用皮膚外用剤組成物の製造方法。
The present invention is as follows.
[1] A mass ratio of a fermented product obtained by fermenting rice bran and legume-derived peptides after fermentation with Bacillus subtilis, and a peptide obtained by hydrolyzing soy protein and a peptide that is at least one of a silk peptide and a mass ratio of 9 : A cell-applied skin external preparation composition obtained by mixing at a ratio of 1-1: 9.
[2] A mass ratio of a fermented product obtained by fermenting rice bran and legume-derived peptides after fermentation with Bacillus subtilis, and a peptide obtained by hydrolyzing soy protein and a peptide that is at least one of a silk peptide and a mass ratio of 9 The manufacturing method of the cell utilization skin external preparation composition characterized by providing the mixing process mixed in the ratio of: 1-1: 9.

本発明の細胞賦活用皮膚外用剤組成物は、天然物を原料としている。よって、本発明の細胞賦活用皮膚外用剤組成物は、安全性が高く、且つ優れたコラーゲン合成作用及び細胞増殖作用等を有する。
本発明の細胞賦活用皮膚外用剤組成物の製造方法によれば、入手が容易な枯草菌を用いて発酵させることにより製造できる。よって、上記の優れた作用を有する本発明の細胞賦活用皮膚外用剤組成物を、小型の製造設備により安全に、且つ容易に製造することができる。
The cell utilization skin external preparation composition of the present invention uses a natural product as a raw material. Therefore, the cell utilization skin external preparation composition of this invention has high safety | security, and has the outstanding collagen synthetic | combination effect | action, cell proliferation effect | action, etc.
According to the manufacturing method of the cell utilization skin external preparation composition of this invention, it can manufacture by fermenting using the Bacillus subtilis easily available. Therefore, the cell utilization skin external preparation composition of this invention which has said outstanding effect | action can be manufactured safely and easily with small manufacturing equipment.

以下、本発明を詳しく説明する。
本発明の細胞賦活用皮膚外用剤組成物は、米ぬかと豆類由来ペプチドとを枯草菌により発酵させた後精製して得られる発酵物と、大豆タンパク質が加水分解されたペプチド及び絹ペプチドの少なくとも1種であるペプチドとを、質量比9:1〜1:9の割合で混合することにより得られたことを特徴とする。本発明の細胞賦活用皮膚外用剤組成物は、更に、ビタミン類を含有することができる。
The present invention will be described in detail below.
The cell utilization skin external preparation composition of the present invention is a fermented product obtained by fermenting rice bran and legume-derived peptides with Bacillus subtilis and then refining them, and a peptide obtained by hydrolyzing soy protein and a silk peptide. It is obtained by mixing the peptide as a seed in a mass ratio of 9: 1 to 1: 9. The cell utilization skin external preparation composition of this invention can contain vitamin A further.

上記「米ぬか」としては、例えば、米ぬか、脱脂米ぬか、米胚芽、及び脱脂米胚芽が挙げられる。これらは1種単独で用いてもよく、2種以上を併用してもよい。上記米ぬかは、市販の米ぬか等に限定されることなく、様々な種類の米ぬかを用いることができる。   Examples of the “rice bran” include rice bran, defatted rice bran, rice germ, and defatted rice germ. These may be used alone or in combination of two or more. The rice bran is not limited to commercially available rice bran, and various types of rice bran can be used.

上記「豆類由来ペプチド」は、豆類に含まれるペプチド又は豆類に含まれるタンパク質に由来するペプチドであれば、その具体的な種類及び構造には特に限定はない。上記「豆類由来ペプチド」は、市販の豆類由来ペプチドに限定されることなく、様々な種類の豆類由来ペプチドを用いることができる。上記豆類由来ペプチドとしては、例えば、大豆ペプチド、小豆ペプチド、エンドウペプチド及びそらまめペプチドが挙げられる。上記豆類由来ペプチドとしては、大豆ペプチドが好ましい。上記豆類由来ペプチドは1種単独で用いてもよく、2種以上を併用してもよい。   As long as the “bean-derived peptide” is a peptide derived from a peptide contained in a bean or a protein contained in a bean, its specific type and structure are not particularly limited. The “bean-derived peptides” are not limited to commercially available bean-derived peptides, and various kinds of bean-derived peptides can be used. Examples of the beans-derived peptide include soybean peptide, red bean peptide, pea peptide, and broad bean peptide. As the bean-derived peptide, soybean peptide is preferable. The legume-derived peptides may be used alone or in combination of two or more.

上記豆類由来ペプチドを得る方法には特に限定はない。例えば、上記豆類由来ペプチドは、豆類(例えば、大豆、小豆、エンドウ及びそらまめ等の1種又は2種以上)を溶媒(水、熱水、アルコール(エタノール等)の有機溶媒又は水−有機溶媒混合溶媒)で抽出することにより得ることができる。この過程において、必要に応じて分画及び精製等を行うことができる。更に、プロテアーゼ、酸又はアルカリで加水分解処理をすることにより、得られた豆類由来ペプチド又は豆類タンパク質を更に断片化することができる。更に、上記豆類由来ペプチドは、化学的にアミノ酸同士をペプチド結合させることにより、あるいは公知の遺伝子工学的手法により、人為的に合成されたペプチドでもよい。   There is no limitation in particular in the method of obtaining the said beans origin peptide. For example, the above-mentioned bean-derived peptide is obtained by using beans (for example, one or more of soybeans, red beans, peas, broad beans, etc.) as a solvent (water, hot water, alcohol (ethanol etc.) organic solvent or water-organic solvent mixture. It can be obtained by extraction with a solvent. In this process, fractionation and purification can be performed as necessary. Furthermore, the obtained legume-derived peptide or legume protein can be further fragmented by subjecting it to a hydrolysis treatment with protease, acid or alkali. Further, the bean-derived peptide may be a peptide artificially synthesized by chemically bonding amino acids to each other or by a known genetic engineering technique.

上記豆類由来ペプチドの形態には特に限定はない。上記豆類由来ペプチドは、上記抽出後、乾燥等により固形化した固形物(例えば、粉状物又は粒状物等)とすることができる。また、上記豆類由来ペプチドとして、上記抽出物自体を用いることができる。即ち、本発明では、上記豆類由来ペプチドとして、上記豆類由来ペプチドを含有する抽出物(豆類エキス、特に大豆エキス等)を用いることができる。例えば、本発明では、上記豆類由来ペプチドとして、豆類(例えば、大豆、小豆、エンドウ及びそらまめ等の1種又は2種以上)を溶媒(水、熱水、アルコール(エタノール等)の有機溶媒又は水−有機溶媒混合溶媒)で抽出することにより得られる抽出物を用いることができる。本発明では、特に大豆ペプチドを含有する抽出物(大豆エキス)等が好ましく用いられる。   There is no particular limitation on the form of the legume-derived peptide. The legume-derived peptide can be a solid (for example, a powdery product or a granular product) solidified by drying or the like after the extraction. Moreover, the said extract itself can be used as said bean origin peptide. That is, in the present invention, an extract containing a bean-derived peptide (bean extract, particularly soybean extract) can be used as the bean-derived peptide. For example, in the present invention, beans (for example, one or more of soybeans, red beans, peas, broad beans, etc.) are used as solvents (water, hot water, organic solvents such as alcohol (ethanol etc.) or water as the beans-derived peptides. An extract obtained by extraction with (organic solvent mixed solvent) can be used. In the present invention, an extract (soybean extract) containing soybean peptide is particularly preferably used.

上記豆類由来ペプチドを含有する抽出物を得るための抽出方法、抽出条件については特に限定はない。例えば、抽出原料である豆類は未粉砕でも、粉砕したものでもよい。また、抽出物の品質を維持できる限り、不純物除去等の前処理をしてもよい。また、抽出溶媒としては、水又は熱水の他、メタノール及びエタノール等のアルコール、酢酸エチル等のエステル、n−ヘキサン等の有機溶媒、並びにこれらの有機溶媒と水又は熱水との混合溶媒等を用いることができる。上記抽出溶媒としては、水又は熱水、アルコール(メタノール及びエタノール等)、及び水又は熱水とアルコールとの混合溶媒が好ましい。上記熱水の温度は、通常、40〜100℃、好ましくは50〜80℃、更に好ましくは50〜70℃である。また、抽出の際の抽出溶媒のpHは通常3〜7、好ましくは4〜6、更に好ましくは4〜5である。pHを上記範囲内とすることにより、抽出原料に含まれている各種成分の安定性を保つことができるので好ましい。抽出温度は特に制限されないが、常温又は加熱抽出が好ましい。加熱抽出の場合、加熱温度としては通常40〜100℃、好ましくは50〜80℃、更に好ましくは50〜70℃である。加熱温度をかかる範囲とすることにより、抽出を効率的に行うことができるので好ましい。   There is no limitation in particular about the extraction method and extraction conditions for obtaining the extract containing the said beans origin peptide. For example, beans that are extraction raw materials may be unground or pulverized. Further, as long as the quality of the extract can be maintained, pretreatment such as impurity removal may be performed. Examples of the extraction solvent include water and hot water, alcohols such as methanol and ethanol, esters such as ethyl acetate, organic solvents such as n-hexane, and mixed solvents of these organic solvents and water or hot water. Can be used. As the extraction solvent, water or hot water, alcohol (such as methanol and ethanol), and a mixed solvent of water or hot water and alcohol are preferable. The temperature of the hot water is usually 40 to 100 ° C, preferably 50 to 80 ° C, more preferably 50 to 70 ° C. In addition, the pH of the extraction solvent during extraction is usually 3 to 7, preferably 4 to 6, and more preferably 4 to 5. By setting the pH within the above range, it is preferable because the stability of various components contained in the extraction raw material can be maintained. The extraction temperature is not particularly limited, but normal temperature or heat extraction is preferable. In the case of heat extraction, the heating temperature is usually 40 to 100 ° C, preferably 50 to 80 ° C, more preferably 50 to 70 ° C. By setting the heating temperature to such a range, extraction can be efficiently performed, which is preferable.

上記米ぬかと上記豆類由来ペプチドとの割合には特に限定はない。通常、上記豆類由来ペプチドを100質量部とした場合に、上記米ぬかの割合は1〜20質量部、好ましくは5〜20質量部、更に好ましくは8〜18質量部である。上記米ぬかが上記範囲であれば、十分なコラーゲン合成作用等を有する発酵物を得ることができる。   There is no particular limitation on the ratio of the rice bran and the beans-derived peptide. Usually, when the said beans origin peptide is 100 mass parts, the ratio of the said rice bran is 1-20 mass parts, Preferably it is 5-20 mass parts, More preferably, it is 8-18 mass parts. If the rice bran is within the above range, a fermented product having a sufficient collagen synthesis action and the like can be obtained.

上記「枯草菌」[バチルス・ズブチルス(Bacillus subtilis)]は、好気性胞子形成細菌の代表的な種類である。上記枯草菌の種類は、安全性が保証されている限り特に限定されない。上記枯草菌としては、例えば、納豆菌[バチルス・ナットウ(Bacillus natto)]等を用いることができる。上記枯草菌としては、入手が容易であり、且つ安価である納豆菌が好ましい。尚、上記枯草菌としては、市販されている一般的な枯草菌を用いることができる。また、コラーゲン合成作用等を有する発酵物が得られる限り、上記枯草菌としては、自然的に、又はニトロソグアニジン等の化学物質、X線及び紫外線等により人為的な変異手段により生成し、菌学的性質が変異した変異株も用いることができる。   The above-mentioned “Bacillus subtilis” [Bacillus subtilis] is a typical type of aerobic spore-forming bacteria. The type of Bacillus subtilis is not particularly limited as long as safety is guaranteed. As the Bacillus subtilis, for example, Bacillus natto [Bacillus natto] or the like can be used. As the Bacillus subtilis, Bacillus natto which is easily available and inexpensive is preferable. In addition, as said Bacillus subtilis, the common Bacillus subtilis marketed can be used. In addition, as long as a fermented product having a collagen synthesizing action or the like is obtained, the Bacillus subtilis may be produced naturally or by an artificial mutation means such as a chemical substance such as nitrosoguanidine, X-rays, ultraviolet rays, etc. Mutant strains with altered morphological properties can also be used.

上記「発酵物」は、上記米ぬかと上記豆類由来ペプチドとを枯草菌により発酵させた後精製して得られる。上記発酵物は通常、上記米ぬか及び上記豆類由来ペプチドを含む培地に枯草菌を摂取し、適切な条件で発酵培養することにより得られる。上記「発酵物」を得るための発酵培養条件には特に限定はない。発酵培養は通常、通気攪拌を行うことにより行われる。また、上記培地についても、上記枯草菌が増殖できる限り特に制限はない。上記培地は通常は液体培地であるが、固形培地でもかまわない。また、上記培地のpH(特に発酵時)は、通常5.5〜8.5、好ましくは6.0〜8.0、更に好ましくは6.5〜7.5である。このpHを上記の範囲内とすると、抽出原料に含まれている各種成分の安定性を保つことができるので好ましい。更に、培養温度についても、発酵が行われる限り特に制限はない。該培養温度は、通常15〜50℃、好ましくは20〜45℃、更に好ましくは30〜45℃、より好ましくは35〜43℃、特に好ましくは35〜37℃である。また、糖等の各種の栄養素並びにpH調製のための酸及びアルカリ等を培地に添加してもよい。更に、上記発酵は、混合発酵でも連続発酵でもよい。 The “fermented product” is obtained by purifying the rice bran and the legume-derived peptide after fermentation with Bacillus subtilis. The fermented product is usually obtained by ingesting Bacillus subtilis into a medium containing the rice bran and the bean-derived peptide and fermenting and culturing under appropriate conditions. The fermentation culture conditions for obtaining the above “fermented product” are not particularly limited. Fermentation culture is usually performed by aeration and agitation. The medium is not particularly limited as long as the Bacillus subtilis can grow. The medium is usually a liquid medium, but may be a solid medium. Moreover, pH (especially at the time of fermentation) of the said culture medium is 5.5-8.5 normally, Preferably it is 6.0-8.0, More preferably, it is 6.5-7.5. If this pH is within the above range, it is preferable because the stability of various components contained in the extraction raw material can be maintained. Further, the culture temperature is not particularly limited as long as fermentation is performed. The culture temperature is usually 15 to 50 ° C, preferably 20 to 45 ° C, more preferably 30 to 45 ° C, more preferably 35 to 43 ° C , and particularly preferably 35 to 37 ° C. In addition, various nutrients such as sugar and acid and alkali for pH adjustment may be added to the medium. Furthermore, the fermentation may be mixed fermentation or continuous fermentation.

上記発酵物の形態には特に限定はない。上記発酵物は、精製されたものであり、発酵培養により得られた発酵液をろ過したままの液でもよい。また、上記発酵物は、上記発酵液に対し、必要に応じて滅菌処理若しくはpH調整をしたり、又はイオン交換樹脂、活性炭カラム若しくは透析膜等を利用し、脱臭・脱色等の後処理をした発酵液でもよい。更に、上記発酵物は、該発酵液を濃縮した濃縮液又はペースト状物でもよい。その他にも、上記発酵物は、該発酵液を凍結乾燥等の公知の方法により溶媒を除去した固形物及び粉末化した粉末物でもよい。更に、上記発酵物は、上記発酵液又は上記固形物及び粉末物を、水若しくはエタノール、プロピレングリコール及び1,3−ブチレングリコール等の有機溶媒、又はこれらの混合溶媒に添加した溶液又は分散液としてもよい。 There is no limitation in particular in the form of the said fermented material. The said fermented material is refine | purified and the liquid which filtered the fermentation liquid obtained by fermentation culture may be sufficient. In addition, the fermented product is subjected to sterilization treatment or pH adjustment, if necessary, or post-treatment such as deodorization / decolorization using an ion exchange resin, an activated carbon column or a dialysis membrane. Fermented liquid may be used. Further, the fermented product may be a concentrated solution or a paste-like product obtained by concentrating the fermented solution. In addition, the fermented product may be a solid product and a powdered product obtained by removing the solvent from the fermented solution by a known method such as freeze drying. Further, the fermented product is a solution or dispersion in which the fermented liquid or the solid and powder are added to water or an organic solvent such as ethanol, propylene glycol and 1,3-butylene glycol, or a mixed solvent thereof. Also good.

上記「ペプチド」は、アミノ酸がペプチド結合により結合したポリペプチドである。尚、上記アミノ酸は、通常はL−アミノ酸であるが、D−アミノ酸でもよく、あるいは両者の混合物でもよい。即ち、上記ペプチドを構成するアミノ酸は、L−アミノ酸、D−アミノ酸及び両者の混合のいずれでもよい。   The “peptide” is a polypeptide in which amino acids are bound by peptide bonds. The amino acid is usually an L-amino acid, but may be a D-amino acid or a mixture of both. That is, the amino acid constituting the peptide may be any of L-amino acids, D-amino acids, and a mixture of both.

上記ペプチドの構造には特に限定はない。上記ペプチドの構造も、直鎖構造のみならず、ジスルフィド結合を含んでいてもよい。上記ペプチドとしては、大豆タンパク質(大豆に含まれるタンパク質)を加水分解することにより得られるペプチド及びシルクフィブロイン等の絹ペプチド(絹に含まれるペプチド及び絹に含まれるタンパク質を加水分解して得られるペプチド)が用いられる。これらのペプチドを用いるので、優れたコラーゲン合成作用及び細胞増殖作用を得ることができる。 There is no particular limitation on the structure of the peptide. The peptide structure may contain not only a linear structure but also a disulfide bond. Examples of the peptides include peptides obtained by hydrolyzing soy protein (proteins contained in soybean) and silk peptides such as silk fibroin (peptides obtained by hydrolyzing peptides contained in silk and proteins contained in silk) ) Is used. Since use of these peptides, it is possible to obtain an excellent collagen synthesis activity and cell proliferation effect.

上記ペプチドを得る方法には特に限定はない。上記ペプチドは通常、各種のタンパク質をプロテアーゼ、酸、又はアルカリ等によって加水分解することにより得ることができる。勿論、具体的な加水分解の方法及び条件には特に限定はない。   The method for obtaining the peptide is not particularly limited. The peptide can be usually obtained by hydrolyzing various proteins with protease, acid, alkali or the like. Of course, the specific hydrolysis method and conditions are not particularly limited.

上記ペプチドのアミノ酸数及び分子量も特に限定はない。上記ペプチドのアミノ酸数の下限は、例えば2、3又は4とすることができる。また、上記ペプチドのアミノ酸数の上限は、例えば、100、80、60又は40とすることができる。上記ペプチドの分子量の下限は、例えば、50、100又は200とすることができる。また、上記ペプチドの分子量の上限としては、例えば、300000、200000、100000、50000又は30000とすることができる。特に細胞増殖作用を目的とする場合は、上記ペプチドとして、高分子量のペプチド、例えば、分子量が40000以上のペプチドを用いることが好ましい。尚、上記ペプチドの分子量は公知の各種の方法により測定することができる。上記ペプチドの分子量は、例えば、SDS−PAGEによる電気泳動法及びHPLCとカラムとによるゲルろ過クロマトグラフィー等によって測定することができる。上記ペプチドのアミノ酸数及び分子量は、タンパク質又はペプチドをプロテアーゼ、酸、又はアルカリ等によって加水分解することにより適宜調節することができる。   The number of amino acids and molecular weight of the peptide are not particularly limited. The lower limit of the number of amino acids of the peptide can be set to 2, 3, or 4, for example. Moreover, the upper limit of the amino acid number of the said peptide can be set to 100, 80, 60, or 40, for example. The lower limit of the molecular weight of the peptide can be, for example, 50, 100, or 200. Moreover, as an upper limit of the molecular weight of the said peptide, it can be set as 300000, 200000, 100,000, 50000, or 30000, for example. In particular, for the purpose of cell proliferation, it is preferable to use a high molecular weight peptide, for example, a peptide having a molecular weight of 40,000 or more as the peptide. The molecular weight of the peptide can be measured by various known methods. The molecular weight of the peptide can be measured, for example, by electrophoresis using SDS-PAGE and gel filtration chromatography using HPLC and a column. The number of amino acids and the molecular weight of the peptide can be appropriately adjusted by hydrolyzing the protein or peptide with a protease, acid, alkali, or the like.

上記ペプチドとして好ましくは、(1)分子量が200〜200000のペプチド、(2)アミノ酸数が4〜40であり、且つ分子量が220〜8000であるペプチド、及び(3)アミノ酸数が2〜3であり、且つ分子量が100以下、100〜250及び250〜500の分子量の異なるペプチドの混合物である。また、これら(1)〜(3)のペプチドとして、シルクフィブロインがより好ましい。これらのペプチドと上記発酵物とを含有させることにより、発酵物のみを含有するときに比べて、より優れたコラーゲン合成作用及び細胞増殖作用を得ることができる。   The peptide is preferably (1) a peptide having a molecular weight of 200 to 200,000, (2) a peptide having 4 to 40 amino acids and a molecular weight of 220 to 8000, and (3) having 2 to 3 amino acids. And a mixture of peptides having different molecular weights of 100 or less, 100 to 250, and 250 to 500. Further, as these peptides (1) to (3), silk fibroin is more preferable. By containing these peptides and the fermented product, a more excellent collagen synthesizing action and cell proliferating action can be obtained than when only the fermented product is contained.

また、上記ペプチドが、大豆タンパク質が加水分解されたものである場合、アミノ酸数が2〜6、且つ分子量が100〜1200であるペプチド好ましい。この大豆タンパク質が加水分解されたペプチドと発酵物とを含有させることにより、発酵物のみを含有するときに比べて、より優れたコラーゲン合成作用及び細胞増殖作用を得ることができる。 Moreover, when the said peptide is what hydrolyzed soybean protein, the peptide whose number of amino acids is 2-6 and whose molecular weight is 100-1200 is preferable. By this soy protein to contain a hydrolyzed peptide and fermented product, than when containing only fermented product can Rukoto obtain better collagen synthesis activity and cell proliferation effect.

上記ペプチドは1種単独で用いてもよく、2種以上を用いてもよい。例えば、上記ペプチドとしては、上記の各種のペプチドのうちの1種のみを用いてもよいし、2種以上を併用してもよい。また、上記ペプチドとして、アミノ酸数及び/又は分子量が異なる2種以上のペプチドを含んでいてもよい。   The said peptide may be used individually by 1 type, and may use 2 or more types. For example, as said peptide, only 1 type in said various peptides may be used, and 2 or more types may be used together. Moreover, the said peptide may contain 2 or more types of peptides from which an amino acid number and / or molecular weight differ.

上記「ビタミンA類」は、イソプレノイド型ポリエンアルコールを基本骨格として有する化合物及び該化合物の誘導体である。上記ビタミンA類として具体的には、例えば、ビタミンA1(レチノール)、ビタミンA2、ビタミンA3及び3,4−ジヒドロレチノール並びにこれらが酸化されたアルデヒド(レチナール等)及びカルボン酸(レチノイン酸)等が挙げられる。また、上記「ビタミンA類」には、薬学的に許容される塩及び薬学的に許容される誘導体をも含む。上記誘導体としては、例えば、上記レチノール等のカルボン酸エステルが挙げられる。上記誘導体としてより具体的には、例えば、酢酸レチノール及びパルミチン酸レチノール等のC1〜C30エステル等が挙げられる。尚、本発明では、上記ビタミン類は1種単独で用いてもよく、2種以上を併用してもよい。 The “vitamins A” are compounds having isoprenoid polyene alcohol as a basic skeleton and derivatives of the compounds. Specific examples of the vitamin A include, for example, vitamin A1 (retinol), vitamin A2, vitamin A3, and 3,4-dihydroretinol, and aldehydes (retinal and the like), carboxylic acids (retinoic acid) and the like in which these are oxidized. Can be mentioned. In addition, the “vitamin A” includes pharmaceutically acceptable salts and pharmaceutically acceptable derivatives. Examples of the derivatives include carboxylic acid esters such as the above retinol. More specifically, examples of the derivative include C1-C30 esters such as retinol acetate and retinol palmitate. In the present invention, the vitamin A may be used alone or in combination of two or more.

本発明において、上記ビタミンA類の含有形態には特に限定はない。上記ビタミンA類自体を本発明の細胞賦活用皮膚外用剤組成物に含有させてもよく、その他の物質と併用して含有させてもよい。例えば、上記ビタミンA類は、シクロデキストリン等のホスト化合物に包接させた包接化合物として、本発明の細胞賦活用皮膚外用剤組成物に含有させることができる。また、上記ビタミンA類は、上記ビタミンA類を含む組成物又は混合物として、本発明の細胞賦活用皮膚外用剤組成物に含有させることができる。例えば、上記ビタミンA類は、肝油等の上記ビタミンA類を含有する組成物として、本発明の細胞賦活用皮膚外用剤組成物に含有させることができる。更に、上記ビタミンA類は、上記ビタミンA類が溶解又は分散した溶液又は分散液として、本発明の細胞賦活用皮膚外用剤組成物に含有させることができる。例えば、上記ビタミンA類を動物油又は植物油に溶解させ、当該溶液を本発明の細胞賦活用皮膚外用剤組成物に含有させることができる。 In the present invention, the form of vitamin A is not particularly limited. The vitamin A itself may be contained in the cell-utilizing skin external preparation composition of the present invention, or may be contained in combination with other substances. For example, the vitamin A can be contained in the cell-utilizing skin external preparation composition of the present invention as an inclusion compound that is included in a host compound such as cyclodextrin. Moreover, the said vitamin A can be contained in the cell utilization skin external preparation composition of this invention as a composition or mixture containing the said vitamin A. For example, the vitamin A can be contained in the cell-utilizing skin external preparation composition of the present invention as a composition containing the vitamin A such as liver oil. Furthermore, the said vitamin A can be contained in the cell utilization skin external preparation composition of this invention as a solution or dispersion liquid in which the said vitamin A melt | dissolved or disperse | distributed. For example, the vitamin A can be dissolved in animal oil or vegetable oil, and the solution can be contained in the cell-utilizing skin external preparation composition of the present invention.

本発明の細胞賦活用皮膚外用剤組成物がビタミンA類を含有する場合、上記発酵物と上記ペプチド及び上記ビタミンA類との割合には特に限定はない。上記発酵物と上記ペプチド及び上記ビタミンA類との合計を100質量%とした場合に、上記発酵物の割合は、通常0.1〜99.9質量%、好ましくは10〜80質量%、更に好ましくは40〜60質量%である。本発明では、上記発酵物と上記ペプチド及び上記ビタミンA類の1種又は2種以上とを含有することにより、コラーゲン合成作用等が向上する。本発明では、上記発酵物と上記ペプチド及び上記ビタミンA類の1種又は2種以上の各々の含有量に大差がない場合、即ち、上記発酵物の質量割合が40〜60質量%であるときは、コラーゲン合成作用等がより向上するため好ましい。 When the cell utilization skin external preparation composition of this invention contains vitamin A, there is no limitation in particular in the ratio of the said fermented material, the said peptide, and the said vitamin A. When the total of the fermented product, the peptide and the vitamin A is 100% by mass, the ratio of the fermented product is usually 0.1 to 99.9% by mass, preferably 10 to 80% by mass, Preferably it is 40-60 mass%. In this invention, a collagen synthetic | combination effect | action etc. improve by containing the said fermented material, the said peptide, and 1 type, or 2 or more types of the said vitamin A. In the present invention, when there is no significant difference in the content of one or more of the fermented product, the peptide and the vitamin A, that is, when the mass ratio of the fermented product is 40 to 60% by mass. Is preferable because collagen synthesis and the like are further improved.

本発明の細胞賦活用皮膚外用剤組成物は、各種の用途に用いることができる。この用途には特に限定はない。本発明の細胞賦活用皮膚外用剤組成物は、例えば、皮膚外用剤等の化粧品、化粧品素材、入浴剤等に用いることができる。 The cell utilization skin external preparation composition of this invention can be used for various uses. There is no particular limitation on this application. The cell utilization skin external preparation composition of this invention can be used for cosmetics, cosmetic raw materials, bath preparations, etc., such as skin external preparations, for example.

本発明の細胞賦活用皮膚外用剤組成物は、化粧品に配合することができる。化粧品に配合する場合、本発明の細胞賦活用皮膚外用剤組成物の配合量には特に限定はない。該配合量は、化粧品の種類等により適量を配合することができる。本発明の細胞賦活用皮膚外用剤組成物の配合量は、化粧品を100質量%とした場合に、0.001〜100質量%、特に0.001〜50質量%とすることができる。本発明の細胞賦活用皮膚外用剤組成物の含有量が上記範囲内であれば、優れたコラーゲン合成作用等を有する化粧品とすることができる。 The cell utilization skin external preparation composition of this invention can be mix | blended with cosmetics. When blended in cosmetics , the blending amount of the cell utilization skin external preparation composition of the present invention is not particularly limited. The blending amount can be blended in an appropriate amount depending on the type of cosmetic. The compounding quantity of the cell utilization skin external preparation composition of this invention can be 0.001-100 mass% when a cosmetics is 100 mass%, and can be 0.001-50 mass% especially. If content of the cell utilization skin external preparation composition of this invention is in the said range, it can be set as the cosmetics which have the outstanding collagen synthetic effect etc.

本発明の細胞賦活用皮膚外用剤組成物含有することができる化粧品の種類も特に限定はない。該化粧品としては、例えば、フリーズドライ、パック、パックシート、ピーリング、パウダー、化粧水、おしろい、固形おしろい、口紅、固形頬紅、ファンデーションクリーム、乳液、ローション、ボディローション、クレンジングローション、洗顔クリーム、スキンケアクリーム、ヘアーリンス、ヘアーリキッド、アイシャドウ及び眉ずみ等が挙げられる。また、これらの化粧品には、その種類により、必要に応じて、他の成分、例えば、植物エキス、ビタミン、ビタミン様物質、ミネラル、低級アルコール類、多価アルコール類、油脂類、界面活性剤、抗酸化剤、紫外線吸収剤、増粘剤、色素、防腐剤及び香料等を添加することもできる。 There is no particular limitation on the type of cosmetics that can contain the cell- utilized skin external preparation composition of the present invention. Examples of the cosmetics include freeze-drying, packs, pack sheets, peeling, powders, skin lotions, white powders, solid white powders, lipsticks, solid blushers, foundation creams, emulsions, lotions, body lotions, cleansing lotions, facial creams, skin care creams. , Hair rinse, hair liquid, eye shadow and eyebrows. In addition, depending on the type of these cosmetics, if necessary, other ingredients such as plant extracts, vitamins, vitamin-like substances, minerals, lower alcohols, polyhydric alcohols, fats and oils, surfactants, Antioxidants, ultraviolet absorbers, thickeners, pigments, preservatives, fragrances and the like can also be added.

本発明の細胞賦活用皮膚外用剤組成物を配合する化粧品としては、特に皮膚外用剤が挙げられる。本発明の細胞賦活用皮膚外用剤組成物は優れたコラーゲン合成作用等を有する。よって、本発明の細胞賦活用皮膚外用剤組成物は、皮膚に塗布して用いる化粧品に特に有用である。本発明の細胞賦活用皮膚外用剤組成物を有効成分として含有する皮膚外用剤は、本発明の細胞賦活用皮膚外用剤組成物と、皮膚外用剤に用いられる他の配合剤とを用いて調製することができる。上記他の配合剤としては、例えば液体油(スクワラン及びホホバ油等)、固体油(ミツロウ及びセチルアルコール等)、各種の活性剤、並びに保湿剤(グリセリン及び1,3ーブチレングリコール等)が挙げられる。この皮膚外用剤の剤形には特に限定はない。この皮膚外用剤は、例えば、ローション、クリーム及び乳液等、目的に応じて種々の剤形とすることができる。この皮膚外用剤において、本発明の細胞賦活用皮膚外用剤組成物の配合量には特に限定はない。本発明の発酵物組成物の配合量は、皮膚外用剤を100質量%とした場合に、0.001〜100質量%、特に0.001〜50質量%とすることができる。本発明の細胞賦活用皮膚外用剤組成物の含有量が上記範囲内であれば、優れたコラーゲン合成作用等を有する皮膚外用剤とすることができる。 Examples of cosmetics containing the cell-utilizing skin external preparation composition of the present invention include skin external preparations. The cell-applied skin external preparation composition of the present invention has an excellent collagen synthesis action and the like. Therefore, the cell utilization skin external preparation composition of this invention is especially useful for the cosmetics used by apply | coating to skin. A skin external preparation containing the cell rejuvenating skin external preparation composition of the present invention as an active ingredient is prepared using the cell rejuvenating skin external preparation composition of the present invention and other compounding agents used for the skin external preparation. can do. Examples of the other compounding agents include liquid oil (such as squalane and jojoba oil), solid oil (such as beeswax and cetyl alcohol), various activators, and humectants (such as glycerin and 1,3-butylene glycol). It is done. There is no particular limitation on the dosage form of the external preparation for skin. This external preparation for skin can be made into various dosage forms according to the purpose, such as lotion, cream and emulsion. In this external preparation for skin, the blending amount of the cell-use skin external preparation composition of the present invention is not particularly limited. The blending amount of the fermented product composition of the present invention can be 0.001 to 100% by mass, particularly 0.001 to 50% by mass, when the skin external preparation is 100% by mass. If content of the cell utilization skin external preparation composition of this invention is in the said range, it can be set as the skin external preparation which has the outstanding collagen synthetic effect etc.

尚、本発明の細胞賦活用皮膚外用剤組成物を配合した配合物を、化粧品素材、入浴剤等として用いることもできる。 In addition, the formulation which mix | blended the cell utilization skin external preparation composition of this invention can also be used as a cosmetic raw material, a bath agent, etc.

本発明の細胞賦活用皮膚外用剤組成物の製造方法は、米ぬかと豆類由来ペプチドとを枯草菌により発酵させた後精製して得られる発酵物と大豆タンパク質が加水分解されたペプチド及び絹ペプチドの少なくとも1種であるペプチドとを、質量比9:1〜1:9の割合で混合する混合工程と、を備えることを特徴とする。 The method for producing a cell-utilizing skin external preparation composition of the present invention comprises a fermented product obtained by fermenting rice bran and a bean-derived peptide with Bacillus subtilis and then purifying it, a peptide obtained by hydrolyzing soy protein, and a silk peptide. A mixing step of mixing at least one peptide at a mass ratio of 9: 1 to 1: 9 .

上記「米ぬか」、上記「豆類由来ペプチド」、上記「枯草菌」、及び上記「ペプチド」については、本発明の発酵物組成物で説明した内容が適用される。 The contents described in the fermented product composition of the present invention are applied to the “rice bran”, the “bean-derived peptide”, the “Bacillus subtilis”, and the “peptide”.

上記「発酵物」は、通常、米ぬかと豆類由来ペプチドとを含有する培地に枯草菌を接種して発酵させる発酵工程、及び、後述する精製工程により得られる。上記「発酵工程」における上記「培地」は、米ぬか及び豆由来ペプチドを含有し、枯草菌が増殖して発酵培養をすることができる培地であればよい。上記培地の種類及び組成には特に限定はない。上記培地は、通常、液体培地であるが、固形培地であってもよい。また、上記培地のpH(特に発酵時)は、通常5.5〜8.5、好ましくは6.0〜8.0、更に好ましくは6.5〜7.5である。また、上記培地には、pH及び栄養条件等を好ましい範囲に調整するため、グルコース等の糖類、プロテアーゼ等の酵素、精製水等の水等を添加することができる。 The “fermented product” is usually obtained by a fermentation process in which Bacillus subtilis is inoculated and fermented in a medium containing rice bran and legume-derived peptides , and a purification process described later . The above-mentioned “medium” in the “fermentation step” may be any medium that contains rice bran and a bean-derived peptide and is capable of fermenting culture by Bacillus subtilis growth. There is no limitation in particular in the kind and composition of the said culture medium. The medium is usually a liquid medium, but may be a solid medium. Moreover, pH (especially at the time of fermentation) of the said culture medium is 5.5-8.5 normally, Preferably it is 6.0-8.0, More preferably, it is 6.5-7.5. Moreover, in order to adjust pH, nutrient conditions, etc. to a preferable range, saccharides, such as glucose, enzymes, such as protease, water, such as purified water, etc. can be added to the said culture medium.

上記発酵の際の培養温度は、発酵が行われる限り特に制限はない。該培養温度は、通常15〜50℃、好ましくは20〜45℃、更に好ましくは30〜45℃、より好ましくは35〜43℃、特に好ましくは35〜37℃である。発酵培養は通常、通気攪拌を行うことにより行われる。 The culture temperature during the fermentation is not particularly limited as long as fermentation is performed. The culture temperature is usually 15 to 50 ° C, preferably 20 to 45 ° C, more preferably 30 to 45 ° C, more preferably 35 to 43 ° C , and particularly preferably 35 to 37 ° C. Fermentation culture is usually performed by aeration and agitation.

発酵工程により得られた発酵物は、精製処理し、その後、ペプチドと混合する。この精製処理の方法は特に限定されない。例えば、発酵液を圧搾し、ろ過することにより、上記発酵物を精製することができる。また、発酵液を圧搾し、ろ過し、次いで、活性炭等による脱臭、脱色処理、及び/又は沈殿物の除去処理をし、その後、再度ろ過することにより、上記発酵物を精製することもできる。
上記発酵工程及び精製工程により得られる上記発酵物の形態も特に限定されない。上記発酵物の形態は、本発明の発酵物組成物で説明した内容が適用される。
The fermented material obtained by the fermentation process is purified and then mixed with the peptide. The method for this purification treatment is not particularly limited. For example, the fermented product can be purified by squeezing and filtering the fermentation broth. Moreover, the said fermented liquor can also be refine | purified by squeezing and filtering a fermentation liquid, and then performing the deodorizing process by activated carbon etc., a decoloring process, and / or the removal process of a deposit, and filtering again after that.
The form of the fermented product obtained by the fermentation process and the purification process is not particularly limited. The content described in the fermented product composition of the present invention is applied to the fermented product.

上記「混合工程」において、上記発酵物と上記ペプチド及びビタミンA類の少なくともペプチドとを混合する方法には特に限定はない。発酵物とペプチドとは各々の形態、及びそれぞれの質量割合等によってホモミキサー等の混合器などの適宜の装置を用いて混合することができる。また、混合時の温度も特に限定されず、発酵物及びペプチドのそれぞれの種類等によって設定することが好ましい。発酵物とペプチドとは、5〜20℃の範囲で必要に応じて冷却しながら混合することができ、35〜85℃の範囲で必要に応じて加熱しながら混合することもできる。 In the “mixing step”, the method for mixing the fermented material with the peptide and at least the peptide of vitamin A is not particularly limited. A fermented material and a peptide can be mixed using appropriate apparatuses, such as mixers, such as a homomixer, according to each form and each mass ratio. Moreover, the temperature at the time of mixing is not specifically limited, It is preferable to set with each kind etc. of fermented material and a peptide. The fermented product and the peptide can be mixed while cooling as necessary in the range of 5 to 20 ° C., and can be mixed while heating as necessary in the range of 35 to 85 ° C.

本発明の製造方法は、更に他の工程を備えていてもよい。   The manufacturing method of the present invention may further include other steps.

以下、本発明を実施例により具体的に説明する。
[1]発酵物組成物の製造
米ぬか3kg、大豆ペプチド0.4kg、グルコース0.5kg、アルカリ性プロテアーゼ0.01kg及び精製水50kgを混合し、培地を調製した。その後、培地のpHを6.0〜8.0に調整し、次いで、納豆菌を接種し、37℃で38時間培養して発酵を行った。その後、発酵液を圧搾及びろ過し、次いで、活性炭により脱色、脱臭した。その後、再度発酵液をろ過して精製することにより、発酵物を製造した。
Hereinafter, the present invention will be specifically described by way of examples.
[1] Production of fermented product composition 3 kg of rice bran, 0.4 kg of soybean peptide, 0.5 kg of glucose, 0.01 kg of alkaline protease and 50 kg of purified water were mixed to prepare a medium. Thereafter, the pH of the medium was adjusted to 6.0 to 8.0, then inoculated with Bacillus natto, and cultured at 37 ° C. for 38 hours for fermentation. Thereafter, the fermentation broth was squeezed and filtered, and then decolorized and deodorized with activated carbon. Then, the fermented material was manufactured by filtering and refine | purifying a fermentation liquid again.

[2]シルクフィブロインを含む発酵物組成物の評価
上記[1]で製造した発酵物、ビタミンC(和光純薬工業社製)、及びシルクフィブロイン(オードレマン社製、商品名「フィブロインシート」)を、それぞれ固形分濃度で2%(質量/体積)となるように、緩衝液(PBS)に溶解した。次いで、該溶液を0.22μmのフィルタによりろ過した。その後、各成分が表1及び表2に記載の濃度となるように該溶液を希釈して混合することにより、実験例2〜15の試料溶液を調製した。また、実験例1は、試料溶液として、上記緩衝液(PBS)を使用した。
[2] Evaluation of Fermented Product Composition Containing Silk Fibroin The fermented product produced in [1] above, vitamin C (manufactured by Wako Pure Chemical Industries, Ltd.), and silk fibroin (manufactured by Audleman, trade name “Fibroin Sheet”) Each was dissolved in a buffer solution (PBS) so that the solid concentration was 2% (mass / volume). The solution was then filtered through a 0.22 μm filter. Then, the sample solution of Experimental Examples 2-15 was prepared by diluting and mixing this solution so that each component might become the density | concentration of Table 1 and Table 2. FIG. In Experimental Example 1, the buffer solution (PBS) was used as a sample solution.

2つの96穴ウエルプレート(表中では「P1」及び「P2」という。)のそれぞれに、1ウエル当たり5000個のヒト皮膚繊維芽細胞を撒布した。次いで、5%FBS添加MEM培地で3日間培養した。5%FBS添加MEM培地に対して実験例1〜15の試料を添加して試料添加培地を調製した。該試料添加培地における実験例1〜15の試料溶液の濃度は1%(質量/体積、但し、上記PBSの質量を除く。)である(従って、培地における発酵物組成物中の各成分の最終濃度は試料溶液中の濃度の1/100である。)。そして、ウエル中の上記5%FBS添加MEM培地を上記試料添加培地に交換し、更に3日間培養した。   Each of two 96-well plates (referred to as “P1” and “P2” in the table) was distributed with 5000 human skin fibroblasts per well. Subsequently, the cells were cultured in a MEM medium supplemented with 5% FBS for 3 days. The sample addition medium was prepared by adding the samples of Experimental Examples 1 to 15 to the MEM medium containing 5% FBS. The concentration of the sample solutions of Experimental Examples 1 to 15 in the sample-added medium is 1% (mass / volume, excluding the mass of PBS) (therefore, the final concentration of each component in the fermentation composition in the medium). The concentration is 1/100 of the concentration in the sample solution.) Then, the 5% FBS-added MEM medium in the well was replaced with the sample-added medium, and further cultured for 3 days.

次いで、「コラーゲンステインキット」(コラーゲン技術研究会製)を用いて、キットに添付されたマニュアルに従ってコラーゲン合成量(μg)を測定した。プレート1(P1)及びプレート2(P2)におけるコラーゲン合成量の平均値を表1及び表2に示す。また、実験例1のコラーゲン合成量を1として、実験例2〜8のコラーゲン合成量の相対値を求めた。同様に、実験例9のコラーゲン合成量を1として、実験例10〜15のコラーゲン合成量の相対値を求めた。この結果を表1及び表2に併記する。尚、表1及び表2において、「VC」はビタミンCを意味し、「SF」はシルクフィブロインを意味する。   Next, using a “collagen stain kit” (manufactured by Collagen Technology Research Group), the amount of collagen synthesis (μg) was measured according to the manual attached to the kit. Tables 1 and 2 show the average values of the amount of collagen synthesis in Plate 1 (P1) and Plate 2 (P2). Moreover, the collagen synthesis amount of Experimental Example 1 was set to 1, and the relative value of the collagen synthesis amount of Experimental Examples 2 to 8 was obtained. Similarly, the collagen synthesis amount of Experimental Example 9 was set to 1, and the relative value of the collagen synthesis amount of Experimental Examples 10 to 15 was obtained. The results are also shown in Tables 1 and 2. In Tables 1 and 2, “VC” means vitamin C, and “SF” means silk fibroin.

Figure 0004945692
Figure 0004945692

Figure 0004945692
Figure 0004945692

表1及び表2より、シルクフィブロインと発酵物とを併用している実験例5〜8及び13〜15では、発酵物のみを用いている実験例3及び11並びにシルクフィブロインのみを用いている実験例4及び12に比べてコラーゲン合成作用に優れていることが分かる。   From Tables 1 and 2, in Experimental Examples 5 to 8 and 13 to 15 in which silk fibroin and a fermented product are used in combination, Experimental Examples 3 and 11 using only the fermented product and an experiment using only silk fibroin It can be seen that the collagen synthesizing action is superior to Examples 4 and 12.

[3]他のシルク原料由来のペプチドを含む発酵物組成物の評価
上記[1]で製造した発酵物、ビタミンC(和光純薬工業社製)、シルクフィブロイン、及び下記シルクペプチド(a)及び(b)を、それぞれ固形分濃度で2%(質量/体積)となるように、緩衝液(PBS)に溶解した。次いで、該溶液を0.22μmのフィルタによりろ過した。その後、各成分が表3〜表5に記載の濃度となるように該溶液を希釈して混合することにより、実験例17〜19、24〜28、及び33〜35の試料溶液を調製した。また、実験例17〜19、24〜28、及び33〜35の試料溶液を体積で等量混合することにより、実験例20〜22、29〜31、及び36の試料溶液を調製した。尚、実験例16、23及び32では、試料溶液として、上記緩衝液(PBS)を使用した。
[3] Evaluation of fermented product composition containing peptides derived from other silk raw materials Fermented product manufactured in [1] above, vitamin C (manufactured by Wako Pure Chemical Industries, Ltd.), silk fibroin, and the following silk peptide (a) and (B) was dissolved in a buffer solution (PBS) so that the solid concentration was 2% (mass / volume). The solution was then filtered through a 0.22 μm filter. Then, the sample solution of Experimental Examples 17-19, 24-28, and 33-35 was prepared by diluting and mixing this solution so that each component might become the density | concentration of Table 3-Table 5. Moreover, the sample solutions of Experimental Examples 20 to 22, 29 to 31, and 36 were prepared by mixing the sample solutions of Experimental Examples 17 to 19, 24 to 28, and 33 to 35 in equal amounts by volume. In Experimental Examples 16, 23 and 32, the buffer solution (PBS) was used as the sample solution.

ビタミンC及びシルクフィブロインは、上記[2]で用いたものと同じである。また、シルクペプチド(a)及び(b)としては下記のものを用いた。尚、シルクペプチド(a)及び(b)はいずれも液体であり、固形分濃度としての終濃度が1%(質量/体積)となるように緩衝液により希釈して用いた。
シルクペプチド(a);コスモ食品社製、商品名「シルクペプチドM−500」
シルクペプチド(b);コスモ食品社製、商品名「シルクペプチドM−500#60」
Vitamin C and silk fibroin are the same as those used in [2] above. Moreover, the following were used as silk peptides (a) and (b). Silk peptides (a) and (b) were both liquids, and were diluted with a buffer solution so that the final concentration as a solid content concentration was 1% (mass / volume).
Silk peptide (a); manufactured by Cosmo Foods, trade name “Silk Peptide M-500”
Silk peptide (b); manufactured by Cosmo Foods, trade name “Silk Peptide M-500 # 60”

上記[2]と同じ方法により、実験例16〜36のコラーゲン合成量(μg)を測定した。プレート1(P1)及びプレート2(P2)におけるコラーゲン合成量の平均値を表3〜表5に示す。また、実験例16、23及び32の各コラーゲン合成量を1として、他の実験例のコラーゲン合成量の相対値を求めた。この結果を表3〜表5に併記する。尚、表3〜表5において、「VC」はビタミンCを意味し、「SF」はシルクフィブロインを意味し、「SP」はシルクペプチドを意味する。   By the same method as [2] above, the collagen synthesis amount (μg) of Experimental Examples 16 to 36 was measured. Tables 3 to 5 show average values of the amount of collagen synthesis in Plate 1 (P1) and Plate 2 (P2). Further, assuming that each collagen synthesis amount of Experimental Examples 16, 23 and 32 was 1, the relative value of the collagen synthesis amount of other experimental examples was obtained. The results are also shown in Tables 3-5. In Tables 3 to 5, “VC” means vitamin C, “SF” means silk fibroin, and “SP” means silk peptide.

Figure 0004945692
Figure 0004945692

Figure 0004945692
Figure 0004945692

Figure 0004945692
Figure 0004945692

表3〜5の結果によれば、シルクフィブロインと発酵物とを併用している実験例22、29及び36では、発酵物のみを用いている実験例18、25及び34、並びにシルクフィブロインのみを用いている実験例19、26及び35に比べて前記と同様により優れたコラーゲン合成作用を有している。更に、シルクペプチドと発酵物とを併用している実験例30及び31も、シルクフィブロインの場合と同様に、より優れたコラーゲン合成作用を有していることが分かる。尚、実験例17、24及び33より、ビタミンCもコラーゲン合成作用を有していることが分かる。しかし、発酵物とビタミンCとを併用した実験例20及びビタミンCとシルクフィブロインとを併用した実験例21では、併用による相乗効果はみられないか、又は極く僅かであることが分かる。従って、発酵物とペプチドとの併用による相乗効果が大きいことが分かる。   According to the results of Tables 3 to 5, in Experimental Examples 22, 29 and 36 in which silk fibroin and fermented material are used in combination, Experimental Examples 18, 25 and 34 using only fermented material, and only silk fibroin are used. Compared with the experimental examples 19, 26 and 35 used, the collagen synthesizing action is more excellent as described above. Furthermore, it turns out that Experimental example 30 and 31 which uses a silk peptide and fermented material together also has the outstanding collagen synthetic | combination effect | action similarly to the case of silk fibroin. From Experimental Examples 17, 24 and 33, it can be seen that vitamin C also has a collagen synthesizing action. However, it can be seen that in Example 20 in which fermented material and vitamin C are used in combination and in Example 21 in which vitamin C and silk fibroin are used in combination, the synergistic effect due to the combination is not observed or very slight. Therefore, it turns out that the synergistic effect by combined use of a fermented material and a peptide is large.

[4]大豆ペプチドを含む発酵物組成物の評価
上記[1]で製造した発酵物、ビタミンC(和光純薬工業社製)、シルクフィブロイン、及び下記大豆ペプチド(a)〜(c)を、それぞれ固形分濃度で2%(質量/体積)となるように、緩衝液(PBS)に溶解した。次いで、該溶液を0.22μmのフィルタによりろ過した。その後、各成分が表6及び表7に記載の濃度となるように該溶液を希釈して混合することにより、実験例38〜43及び49〜54の試料溶液を調製した。また、実験例38〜43及び49〜54の試料溶液を体積で等量混合することにより、実験例44〜47及び55〜56の試料溶液を調製した。尚、実験例37及び48では、試料溶液として、上記緩衝液(PBS)を使用した。
[4] Evaluation of fermented product composition containing soybean peptide Fermented product produced in [1] above, vitamin C (manufactured by Wako Pure Chemical Industries, Ltd.), silk fibroin, and the following soybean peptides (a) to (c) Each was dissolved in a buffer solution (PBS) so that the solid concentration was 2% (mass / volume). The solution was then filtered through a 0.22 μm filter. Then, the sample solution of Experimental Examples 38-43 and 49-54 was prepared by diluting and mixing this solution so that each component might become the density | concentration of Table 6 and Table 7. Moreover, the sample solutions of Experimental Examples 44 to 47 and 55 to 56 were prepared by mixing equal amounts of the sample solutions of Experimental Examples 38 to 43 and 49 to 54 by volume. In Experimental Examples 37 and 48, the buffer solution (PBS) was used as the sample solution.

ビタミンC及びシルクフィブロインは、上記[2]で用いたものと同じである。また、大豆ペプチド(a)〜(c)としては下記のものを用いた。尚、大豆ペプチド(a)、(b)及び(c)はいずれも液体であり、固形分濃度としての終濃度が1%(質量/体積)となるように緩衝液により希釈して用いた。
大豆ペプチド(a);不二製油社製、商品名「ハイニュートSMP」
大豆ペプチド(b);不二製油社製、商品名「ハイニュートR」
大豆ペプチド(c);不二製油社製、商品名「ハイニュートDC5」
Vitamin C and silk fibroin are the same as those used in [2] above. Moreover, the following were used as soybean peptides (a) to (c). The soybean peptides (a), (b) and (c) were all liquids, and were diluted with a buffer solution so that the final concentration as a solid content concentration was 1% (mass / volume).
Soy peptide (a): Fuji Oil Co., Ltd., trade name “High New SMP”
Soy peptide (b): Fuji Oil Co., Ltd., trade name “High New R”
Soybean peptide (c): Fuji Oil Co., Ltd., trade name “High New DC5”

上記[2]と同じ方法により、実験例37〜47のコラーゲン合成量(μg)を測定した。プレート1(P1)及びプレート2(P2)におけるコラーゲン合成量の平均値を表6に示す。また、実験例37のコラーゲン合成量を1として、他の実験例のコラーゲン合成量の相対値を求めた。この結果を表6に併記する。尚、表6において、「VC」はビタミンCを意味し、「SF」はシルクフィブロインを意味し、「SBP(a)〜(c)」は大豆ペプチド(a)〜(c)を意味する。   By the same method as [2] above, the collagen synthesis amount (μg) of Experimental Examples 37 to 47 was measured. Table 6 shows the average value of the amount of collagen synthesis in plate 1 (P1) and plate 2 (P2). Further, assuming that the collagen synthesis amount of Experimental Example 37 was 1, the relative value of the collagen synthesis amount of the other Experimental Examples was determined. The results are also shown in Table 6. In Table 6, “VC” means vitamin C, “SF” means silk fibroin, and “SBP (a) to (c)” means soybean peptides (a) to (c).

Figure 0004945692
Figure 0004945692

2つの96穴ウエルプレートのそれぞれに、1ウエル当たり2000個のヒト皮膚繊維芽細胞を撒布した。次いで、5%FBS添加MEM培地で3日間培養した。その後、無血清MEM培地に交換し、更に1日間培養した。0.5%血清添加MEM培地に対して実験例48〜56の試料を添加して試料添加培地を調製した。該試料添加培地における上記実験例48〜56の試料溶液の濃度は1%(質量/体積、但し、上記PBSの質量を除く。)である(従って、培地における発酵物組成物中の各成分の最終濃度は試料溶液中の濃度の1/100である。)。そして、ウエル中の上記無血清MEM培地を上記試料添加培地に交換し、更に4日間培養した。   Each of two 96-well plates was spread with 2000 human skin fibroblasts per well. Subsequently, the cells were cultured in a MEM medium supplemented with 5% FBS for 3 days. Thereafter, the medium was replaced with a serum-free MEM medium and further cultured for 1 day. Samples of Experimental Examples 48 to 56 were added to a MEM medium supplemented with 0.5% serum to prepare a sample-added medium. The concentration of the sample solutions of Experimental Examples 48 to 56 in the sample-added medium is 1% (mass / volume, excluding the mass of PBS) (therefore, the concentration of each component in the fermentation composition in the medium). The final concentration is 1/100 of the concentration in the sample solution.) Then, the serum-free MEM medium in the well was replaced with the sample-added medium, and further cultured for 4 days.

その後、同仁堂「セルカウンティングキット8」に基づき、WST−8テトラゾリウム塩を発色基質とし、生細胞内の脱水素酵素により還元されて生成した水溶性ホルマザンを450nmの波長で測定することにより、吸光度を測定した(生細胞数は当該吸光度の値に比例する。)。また、実験例48の生細胞数を1として、他の実験例の生細胞量の相対値を算出し、細胞増殖作用を評価した。結果を表7に併記する。尚、表7において、「VC」はビタミンCを意味し、「SF」はシルクフィブロインを意味し、「SBP(a)〜(c)」は大豆ペプチド(a)〜(c)を意味する。また、表7における細胞増殖率の項の平均値は、上記吸光度の値の平均値である。   Then, based on Dojindo “Cell Counting Kit 8”, the absorbance was measured by measuring the water-soluble formazan produced by reduction by a dehydrogenase in living cells at a wavelength of 450 nm using WST-8 tetrazolium salt as a chromogenic substrate. It was measured (the number of living cells is proportional to the absorbance value). Further, assuming that the number of living cells in Experimental Example 48 was 1, the relative value of the amount of living cells in other Experimental Examples was calculated, and the cell proliferation action was evaluated. The results are also shown in Table 7. In Table 7, “VC” means vitamin C, “SF” means silk fibroin, and “SBP (a) to (c)” means soybean peptides (a) to (c). Moreover, the average value of the term of cell growth rate in Table 7 is the average value of the absorbance values.

Figure 0004945692
Figure 0004945692

表6より、シルクフィブロインと発酵物とを併用している実験例44は、発酵物のみを用いている実験例39及びシルクフィブロインのみを用いている実験例40に比べて、より優れたコラーゲン合成作用を有することが分かる。更に、発酵物と大豆ペプチドとを併用している実験例45〜47も、シルクフィブロインの場合と同様に、より優れたコラーゲン合成作用を有することが分かる。   From Table 6, Experimental Example 44 in which silk fibroin and fermented material are used in combination is superior in collagen synthesis to Experimental Example 39 using only fermented material and Experimental Example 40 using only silk fibroin. It turns out that it has an effect | action. Furthermore, it turns out that Experimental Example 45-47 which uses fermented material and a soybean peptide together also has the collagen synthesis effect | action excellent in the same way as the case of silk fibroin.

表7より、発酵物と大豆ペプチド(c)とを併用している実験例56は、発酵物のみを用いている実験例50に比べて細胞増殖作用がより向上していることが分かる。更に、発酵物とシルクフィブロインとを併用した実験例55も、同様に細胞増殖作用が向上していることが分かる。   From Table 7, it can be seen that Experimental Example 56 using both the fermented product and soybean peptide (c) has a more improved cell proliferation effect than Experimental Example 50 using only the fermented product. Furthermore, it can be seen that Experimental Example 55 using both fermented material and silk fibroin also improves the cell proliferation action.

[5]ビタミンA類を含む発酵物組成物の評価
上記[1]で製造した発酵物、ビタミンC(和光純薬工業社製)、及びシクロデキストリン包接レチノール(商品名「CAVAMAX W8/Retinol Complex」 シクロケム社製)を、それぞれ固形分濃度で2%(質量/体積)となるように、緩衝液(PBS)に溶解した。次いで、該溶液を0.22μmのフィルタによりろ過した。その後、各成分が表8に記載の濃度となるように該溶液を希釈して混合することにより、実験例58〜66の試料溶液を調製した。尚、実験例57では、試料溶液として、上記緩衝液(PBS)を使用した。
[5] Evaluation of fermented product composition containing vitamins A fermented product produced in the above [1], vitamin C (manufactured by Wako Pure Chemical Industries, Ltd.), and cyclodextrin inclusion retinol (trade name “CAVAMAX W8 / Retinol Complex” Cyclochem Co., Ltd.) was dissolved in a buffer solution (PBS) so that the solid concentration was 2% (mass / volume). The solution was then filtered through a 0.22 μm filter. Then, the sample solution of Experimental Examples 58-66 was prepared by diluting and mixing this solution so that each component might become the density | concentration of Table 8. In Experimental Example 57, the buffer solution (PBS) was used as the sample solution.

上記[2]及び[4]記載の方法と同じ方法により、実験例57〜66のコラーゲン合成量(μg)及び細胞増殖率を測定した。その平均値を表8に示す。また、実験例57のコラーゲン合成量及び生細胞量を1として、他の実験例のコラーゲン合成量及び生細胞量の相対値を求めた。この結果を表8に併記する。尚、表8において、「VC」はビタミンCを意味し、「CDR」はシクロデキストリン包接レチノールを意味する。また、表8における細胞増殖率の項の平均値は、吸光度の値の平均値である。   The collagen synthesis amount (μg) and cell proliferation rate of Experimental Examples 57 to 66 were measured by the same method as described in [2] and [4] above. The average value is shown in Table 8. Further, assuming that the amount of collagen synthesis and the amount of living cells in Experimental Example 57 was 1, relative values of the amount of collagen synthesis and the amount of living cells in other Experimental Examples were obtained. The results are also shown in Table 8. In Table 8, “VC” means vitamin C, and “CDR” means cyclodextrin inclusion retinol. Moreover, the average value of the term of cell growth rate in Table 8 is the average value of absorbance values.

Figure 0004945692
Figure 0004945692

表8より、レチノールと発酵物とを併用している実験例64〜66は、発酵物のみを用いている実験例59及びレチノールのみを用いている実験例60〜63に比べて、優れたコラーゲン合成作用及び細胞増殖作用を有することが分かる。   From Table 8, Experimental Examples 64 to 66 using both retinol and fermented product are superior to those of Experimental Example 59 using only fermented product and Experimental Examples 60 to 63 using only retinol. It can be seen that it has a synthetic action and a cell proliferation action.

[6]ペプチド及びビタミンA類を含む発酵物組成物の評価
上記[1]で製造した発酵物、上記シルクフィブロイン、上記大豆ペプチド(a)、及び上記シクロデキストリン包接レチノールを、それぞれ固形分濃度で2%(質量/体積)となるように、緩衝液(PBS)に溶解した。次いで、該溶液を0.22μmのフィルタによりろ過した。その後、各成分が表9及び表10に記載の濃度となるように該溶液を希釈して混合することにより、実験例68、69、71及び72の試料溶液を調製した。尚、実験例67及び70では、試料溶液として、上記緩衝液(PBS)を使用した。
[6] Evaluation of fermented product composition containing peptide and vitamin A The fermented product produced in the above [1], the silk fibroin, the soy peptide (a), and the cyclodextrin inclusion retinol are each in a solid content concentration. To 2% (mass / volume) in a buffer solution (PBS). The solution was then filtered through a 0.22 μm filter. Then, the sample solutions of Experimental Examples 68, 69, 71, and 72 were prepared by diluting and mixing the solutions so that each component had a concentration described in Table 9 and Table 10. In Experimental Examples 67 and 70, the buffer solution (PBS) was used as the sample solution.

上記[2]及び[4]と同じ方法により、実験例67〜72のコラーゲン合成量(μg)及び細胞増殖率を測定した。その平均値を表9及び表10に示す。また、実験例67及び70のコラーゲン合成量及び生細胞量を1として、他の実験例のコラーゲン合成量及び生細胞量の相対値を求めた。この結果を表9及び表10に併記する。尚、表9及び表10において、「SF」はシルクフィブロインを意味し、「SBP」は大豆ペプチドを意味し、「CDR」はシクロデキストリン包接レチノールを意味する。また、表9及び表10における細胞増殖率の項の平均値は、吸光度の値の平均値である。   By the same method as in the above [2] and [4], the collagen synthesis amount (μg) and cell proliferation rate of Experimental Examples 67 to 72 were measured. The average values are shown in Tables 9 and 10. Moreover, the collagen synthesis amount and the amount of living cells in Experimental Examples 67 and 70 were taken as 1, and the relative values of the amount of collagen synthesis and the amount of living cells in other Experimental Examples were determined. The results are also shown in Table 9 and Table 10. In Tables 9 and 10, “SF” means silk fibroin, “SBP” means soybean peptide, and “CDR” means cyclodextrin inclusion retinol. Moreover, the average value of the term of cell growth rate in Table 9 and Table 10 is the average value of the absorbance value.

Figure 0004945692
Figure 0004945692

Figure 0004945692
Figure 0004945692

表10より、レチノール及びペプチドと発酵物とを併用している実験例69及び72は、優れたコラーゲン合成作用及び細胞増殖作用を有することが分かる。   From Table 10, it can be seen that Experimental Examples 69 and 72 in which retinol and a peptide are used in combination with a fermented product have excellent collagen synthesis action and cell proliferation action.

尚、本発明は、上記具体的実施例に限定されない。本発明は、目的、用途に応じて本発明の範囲内で種々変更することができる。   In addition, this invention is not limited to the said specific Example. The present invention can be variously modified within the scope of the present invention depending on the purpose and application.

本発明の発酵物組成物は、安全性に優れ、コラーゲン合成作用等を有する。本発明の発酵物組成物は、皮膚外用剤等の各種の化粧品並びに健康食品及び機能性食品等の各種の飲食物等に配合して用いることができる。即ち、本発明は、化粧品及び飲食物等の分野において利用することができる。   The fermented product composition of the present invention is excellent in safety and has a collagen synthesis action and the like. The fermented product composition of the present invention can be used by blending it with various cosmetics such as external preparations for skin and various foods such as health foods and functional foods. That is, the present invention can be used in the fields of cosmetics and foods and drinks.

Claims (2)

米ぬかと豆類由来ペプチドとを枯草菌により発酵させた後精製して得られる発酵物と、大豆タンパク質が加水分解されたペプチド及び絹ペプチドの少なくとも1種であるペプチドとを、質量比9:1〜1:9の割合で混合することにより得られたことを特徴とする細胞賦活用皮膚外用剤組成物。A fermented product obtained by fermenting rice bran and legume-derived peptides after fermentation with Bacillus subtilis and a peptide obtained by hydrolyzing soy protein and a peptide that is at least one of a silk peptide and a mass ratio of 9: 1 to 1 A cell-utilizing skin external preparation composition characterized by being obtained by mixing at a ratio of 1: 9. 米ぬかと豆類由来ペプチドとを枯草菌により発酵させた後精製して得られる発酵物と、大豆タンパク質が加水分解されたペプチド及び絹ペプチドの少なくとも1種であるペプチドとを、質量比9:1〜1:9の割合で混合する混合工程を備えることを特徴とする細胞賦活用皮膚外用剤組成物の製造方法。A fermented product obtained by fermenting rice bran and legume-derived peptides after fermentation with Bacillus subtilis and a peptide obtained by hydrolyzing soy protein and a peptide that is at least one of a silk peptide and a mass ratio of 9: 1 to 1 The manufacturing method of the cell utilization skin external preparation composition characterized by including the mixing process mixed in the ratio of 1: 9.
JP2011111820A 2006-05-02 2011-05-18 Cell-utilized skin external preparation composition and method for producing the same Active JP4945692B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011111820A JP4945692B2 (en) 2006-05-02 2011-05-18 Cell-utilized skin external preparation composition and method for producing the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006128692 2006-05-02
JP2006128692 2006-05-02
JP2011111820A JP4945692B2 (en) 2006-05-02 2011-05-18 Cell-utilized skin external preparation composition and method for producing the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008514485A Division JP4945556B2 (en) 2006-05-02 2007-05-02 Cell application skin external preparation composition

Publications (2)

Publication Number Publication Date
JP2011173921A JP2011173921A (en) 2011-09-08
JP4945692B2 true JP4945692B2 (en) 2012-06-06

Family

ID=38667782

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008514485A Active JP4945556B2 (en) 2006-05-02 2007-05-02 Cell application skin external preparation composition
JP2011111820A Active JP4945692B2 (en) 2006-05-02 2011-05-18 Cell-utilized skin external preparation composition and method for producing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008514485A Active JP4945556B2 (en) 2006-05-02 2007-05-02 Cell application skin external preparation composition

Country Status (5)

Country Link
JP (2) JP4945556B2 (en)
KR (1) KR101397976B1 (en)
CN (2) CN101431980B (en)
HK (1) HK1130182A1 (en)
WO (1) WO2007129674A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4537486B2 (en) * 2009-01-19 2010-09-01 国立大学法人秋田大学 Method for producing rice bran leachate from which bad smell was removed, method for producing rice bran leachate from which bad smell was removed, and method for producing γ-aminobutyric acid
KR20130058107A (en) * 2011-11-25 2013-06-04 (주)아모레퍼시픽 Isolation and preparation of small peptides from soybean and its cosmetic composition
CN102846537B (en) * 2012-10-18 2014-01-29 天津市可美国际贸易有限公司 Preparation method of skin care essence stoste
JP6332941B2 (en) * 2013-11-01 2018-05-30 株式会社東洋発酵 Oral composition for beauty health
CN106466291B (en) * 2015-08-19 2019-06-07 德州昂立达生物技术有限公司 A kind of still cleaning products and preparation method thereof containing fermented grain object
CN105596286A (en) * 2016-01-25 2016-05-25 广州保税区雅兰国际化妆品有限公司 Yeast skin-whitening cosmetic composition and preparation method thereof
CN110484569A (en) * 2019-09-18 2019-11-22 上海应用技术大学 A kind of meter of source fermentation material and the preparation method and application thereof
CN112022792B (en) * 2020-09-27 2022-12-09 黑龙江省中医药科学院 Preparation method of edible traditional Chinese medicine hair dye with homology of medicine and food

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3417419B2 (en) * 1992-07-13 2003-06-16 株式会社資生堂 External preparation for skin
JP3625501B2 (en) * 1994-10-06 2005-03-02 御木本製薬株式会社 Method for producing raw material for skin-applied skin and cell-applied skin external agent
JPH10234301A (en) * 1997-02-27 1998-09-08 Meiji Seika Kaisha Ltd Green tea beverage
DE19713092A1 (en) * 1997-03-27 1998-10-01 Wacker Chemie Gmbh Complexes of gamma-cyclodextrin and retinol or retinol derivatives, as well as processes for their preparation and their use
JP4755325B2 (en) * 1997-11-04 2011-08-24 一丸ファルコス株式会社 Bioactive composition derived from silk protein hydrolyzate
JP2000327538A (en) * 1999-05-24 2000-11-28 Toyo Hakko:Kk Agent composition for hair treatment
JP2001000140A (en) * 1999-06-22 2001-01-09 Bizen Kasei Kk Composition for removing active oxygen, and its production
JP2001120222A (en) * 1999-10-28 2001-05-08 Bizen Kasei Kk Composition for suppressing formation of peroxy lipids and production therefor
US20040234560A1 (en) * 2001-04-06 2004-11-25 Akihiko Kimura Cosmetic materials and process for producing the same
WO2004009731A1 (en) * 2002-07-23 2004-01-29 Fuji Oil Company, Limited Antioxidant and process for producing the same
JP2005080655A (en) * 2003-09-10 2005-03-31 Suetsuna Yoko New composition containing isoflavone and activated oxygen inhibitor
JP4387760B2 (en) * 2003-10-24 2009-12-24 株式会社ラティアクリエイツ Antioxidant composition
JP2005143480A (en) * 2003-11-17 2005-06-09 Hasegawa Hidetoshi Method for producing industrial waste such as rice bran, soybean-curd refuse, beer lees and the like
JP2006213688A (en) * 2005-02-07 2006-08-17 Toshio Oshiro Nk(natural killer) activity enhancer

Also Published As

Publication number Publication date
CN102225045A (en) 2011-10-26
JPWO2007129674A1 (en) 2009-09-17
JP4945556B2 (en) 2012-06-06
KR101397976B1 (en) 2014-05-27
CN101431980B (en) 2012-08-01
CN101431980A (en) 2009-05-13
JP2011173921A (en) 2011-09-08
CN102225045B (en) 2013-01-02
HK1130182A1 (en) 2009-12-24
WO2007129674A1 (en) 2007-11-15
KR20090007726A (en) 2009-01-20

Similar Documents

Publication Publication Date Title
JP4945692B2 (en) Cell-utilized skin external preparation composition and method for producing the same
JP5018171B2 (en) Plant-derived activator and extracellular matrix production promoter
JPWO2007148739A1 (en) Plant-derived cell activator, anti-aging agent, and extracellular matrix production promoter
JPWO2007148737A1 (en) Method for preparing plant extract, plant extract and use thereof
JP2023091082A (en) Antipollution agent and topical skin composition
JP2003063925A (en) Skin care preparation
JP2003073225A (en) Cosmetic
JP2002332224A (en) Anti-ageing skin care preparation and anti-ageing skin care preparation composition
JP2000191494A (en) Composition for beauty culture and health
JP2015074623A (en) New derivative having collagen production effect, and manufacturing method thereof
JP2011195537A (en) Antioxidant, whitening agent, anti-aging agent, hair tonic, humectant, skin care preparation and functional oral composition
JP2003252742A (en) Melanocyte dendrite formation inhibitor and skin care preparation containing the same
JP4203325B2 (en) Skin external preparation and skin external preparation composition
JP4713032B2 (en) Skin preparation
JPH11240817A (en) Beauty culture pack
JP3895636B2 (en) Anti-aging agent and external preparation for skin using the same
KR101951646B1 (en) A cosmetic composition comprising marinobacter-fermented spirulina extract for antioxydant and skin winkle improvement
JP2004067549A (en) External preparation for skin
JP5578160B2 (en) Plant-derived activator and extracellular matrix production promoter
TWI393780B (en) A fermentation composition, a cosmetic composition, and the like
WO2022181153A1 (en) Intracellular polyamine enhancer and production method therefor
JP2003252741A (en) Skin care preparation
JP7015775B2 (en) Polyphenol derivative exhibiting gene repair action
JP4653361B2 (en) Skin preparation
JP2002193820A (en) Skin care preparation and skin care preparation composition

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110823

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120221

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120305

R150 Certificate of patent or registration of utility model

Ref document number: 4945692

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250